ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)] Meeting Abstract

  

Authors:	Ullrich, R.; Wermke, M.; Yachnin, J.; Mielke, S.; Patel, R.; Yushak, M. L.; Schoenfeld, A. J.; Desai, J.; Altan, M.; D'Angelo, S. P.; Noujaim, J.; Haanen, J. B. A. G.; Powers, B.; Faitg, T.; Liu, W.; Patel, N.; Araujo, D. M.
Abstract Title:	ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma, myxoid/round cell liposarcoma and nonsmall cell lung cancer [Substudy 1 (GSK3901961) and Substudy 2 (GSK3845097)]
Meeting Title:	2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung
Journal Title:	Oncology Research and Treatment
Volume:	45
Issue:	Suppl. 3
Meeting Dates:	2022 Nov 13-16
Meeting Location:	Berlin, Germany
ISSN:	2296-5270
Publisher:	S. Karger AG
Date Published:	2022-11-01
Start Page:	54
Language:	English
ACCESSION:	WOS:000883051700120
PROVIDER:	wos
DOI:	10.1159/000521004
Notes:	Meeting Abstract: 700 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/202423